





European Federation of Pharmaceutical  
Industries and Associations



# Working together, to elevate the life science sector in Japan



10 October 2024  
Lars Fruergaard Jørgensen  
*EFPIA President*




# EFPIA vision, mission, and purpose of EFPIA Japan Days 2024

Our vision is for a **healthier future** based on prevention, innovation, access to **new treatments and better outcomes for patients.**

EFPIA's mission is to **create a collaborative environment** that enables our members to **innovate, discover**, develop and deliver new therapies and vaccines for **patients**, as well as contribute to the economy.

# EFPIA proposals to further strengthen Japan's life science sector



**Maintaining political ambition for the life science sector as a core strategic sector**



**Broaden and embed a commitment to the life science sector across government and institutions**



**Continue to strengthen market conditions and address regulatory hurdles**

# Maintain political ambition for the life science sector as a core strategic sector with incoming PM Ishiba



POLITICAL GUIDELINES  
FOR THE NEXT EUROPEAN  
COMMISSION 2024–2029  
**President Ursula von der Leyen**

The **EU** commission has called for a **new life science strategy** and European Biotech Act to accelerate **innovation**

and stated that to **lead innovation** it needs to test and develop ideas through **new public-private partnerships**



**Former Prime Minister Kishida**  
Gate Opening Summit for  
Innovative Drug Discovery



Former PM Kishida called the **pharmaceutical industry** an important industry that will become the **core of future economic growth**

and stated that a **new strategic public-private dialogue** is required for a thriving life-sciences ecosystem

# Broaden and embed the commitment to the life science sector across government and institutions

Holistic approach through...



**Cross ministerial and institutional anchoring**



**Inclusive platform for Public Private Dialogue (PPD)**



**Permanent predictable funding**

# European PPDs embedded in the life science strategy



Examples of governments which have elevated the life science sector



Investments in **R&D +60%**  
**Leading in clinical trials** per inhabitants  
**+100% export** of goods



**2nd highest health research** budget per GDP globally  
**Medical citations 3rd** highest globally  
**+20% in** clinical trials conducted in UK




¥ **1.2 trillion** for Health innovation  
 ¥ **125 billion** for R&D of biomedicines  
 Increased **public-private partnerships**

# Continue to strengthen market conditions and address regulatory hurdles

Encourage innovation and build a more attractive and competitive life-science ecosystem


Improve predictability of market frameworks...



Enable the creation of attractive markets for innovation



...reduce barriers towards innovation



**Thank You!**

